-
JAMA Oncology
Brief Report
April 25, 2024
Giacomo聽Montagna,听惭顿, MPH; Mary M.听Mrdutt,听惭顿, MS; Susie X.听Sun,听惭顿; Callie聽Hlavin,听惭顿, MPH; Emilia J.听Diego,听惭顿; Stephanie M.听Wong,听惭顿, MPH; Andrea V.听Barrio,听惭顿; Astrid Botty聽van den Bruele,听惭顿; Neslihan聽Cabioglu,听惭顿, PhD; Varadan聽Sevilimedu,聽MBBS, DrPH; Laura H.听Rosenberger,听惭顿, MS; E. Shelley聽Hwang,听惭顿, MPH; Abigail聽Ingham,聽MBchB; B盲rbel聽Papassotiropoulos,听惭顿; Bich Doan聽Nguyen-Str盲uli,听惭顿; Christian聽Kurzeder,听惭顿; Danilo D铆az聽Aybar,听惭顿; Denise聽Vorburger,听惭顿; Dieter Michael聽Matlac,听惭顿; Edvin聽Ostapenko,听惭顿; Fabian聽Riedel,听惭顿; Florian聽Fitzal,听惭顿; Francesco聽Meani,听惭顿; Franziska聽Fick,听惭顿; Jacqueline聽Sagasser,听惭顿; J枚rg聽Heil,听惭顿, PhD; Hasan聽Karanl谋k,听惭顿; Konstantin J.听Dedes,听惭顿; Laszlo聽Romics,听惭顿, PhD; Maggie聽Banys-Paluchowski,听惭顿, PhD; Mahmut聽Muslumanoglu,听惭顿; Maria Del Rosario Cueva聽Perez,听惭顿; Marcelo Ch谩vez聽D铆az,听惭顿; Martin聽Heidinger,听惭顿; Mathias K.听Fehr,听惭顿; Mattea聽Reinisch,听惭顿; Mustafa聽Tukenmez,听惭顿; Nadia聽Maggi,听惭顿; Nicola聽Rocco,听惭顿, PhD; Nina聽Ditsch,听惭顿, PhD; Oreste Davide聽Gentilini,听惭顿; Regis R.听Paulinelli,听惭顿, PhD; Sebasti谩n Sol茅聽Zarhi,听惭顿; Sherko聽Kuemmel,听惭顿, PhD; Simona聽Bruzas,听惭顿; Simona聽di Lascio,听惭顿; Tamara K.听Parissenti,听惭顿; Tanya L.听Hoskin,聽MS; Uwe聽G眉th,听惭顿; Valentina聽Ovalle,听惭顿; Christoph聽Tausch,听惭顿; Henry M.听Kuerer,听惭顿, PhD; Abigail S.听Caudle,听惭顿; Jean-Francois聽Boileau,听惭顿, MSc; Judy C.听Boughey,听惭顿; Thorsten聽K眉hn,听惭顿, PhD; Monica聽Morrow,听惭顿; Walter P.听Weber,听惭顿
online first
JAMA Oncol. 2024; 10.1001/jamaoncol.2024.0578
This cohort study examines oncological outcomes after sentinel lymph node biopsy with dual-tracer mapping or targeted axillary dissection.
-
榴莲视频 Network Open
Original Investigation
Oncology
December 28, 2023
Beverly聽Kyalwazi,听惭顿; Christina聽Yau,聽PhD; Michael J.听Campbell,聽PhD; Toshio F.听Yoshimatsu,聽MS; A. Jo聽Chien,听惭顿; Anne M.听Wallace,听惭顿; Andres聽Forero-Torres,听惭顿; Lajos聽Pusztai,听惭顿, DPhil; Erin D.听Ellis,听惭顿; Kathy S.听Albain,听惭顿; Anne H.听Blaes,听惭顿; Barbara B.听Haley,听惭顿; Judy C.听Boughey,听惭顿; Anthony D.听Elias,听惭顿; Amy S.听Clark,听惭顿, MSCE; Claudine J.听Isaacs,听惭顿; Rita聽Nanda,听惭顿; Hyo S.听Han,听惭顿; Rachel L.听Yung,听惭顿; Debasish聽Tripathy,听惭顿; Kristen K.听Edmiston,听惭顿; Rebecca K.听Viscusi,听惭顿; Donald W.听Northfelt,听惭顿; Qamar J.听Khan,听惭顿; Smita M.听Asare,聽BS; Amy聽Wilson,聽BS; Gillian L.听Hirst,聽PhD; Ruixiao聽Lu,聽PhD; William Fraser聽Symmans,聽MBChB; Douglas聽Yee,听惭顿; Angela M.听DeMichele,听惭顿; Laura J.听van 鈥檛 Veer,聽PhD; Laura J.听Esserman,听惭顿, MBA; Olufunmilayo I.听Olopade,听惭顿
open access
榴莲视频 Netw Open. 2023; 6(12):e2349646. 10.1001/jamanetworkopen.2023.49646
This cohort study evaluates pathologic complete response and distant recurrence鈥揻ree survival of early breast cancer by race and whether gene expression signatures correlate with outcomes.
-
榴莲视频 Network Open
Original Investigation
Oncology
September 14, 2023
Helen M.听Johnson,听惭顿; Heather聽Lin,聽PhD; Yu聽Shen,聽PhD; Emilia J.听Diego,听惭顿; Savitri聽Krishnamurthy,听惭顿; Wei T.听Yang,聽MBBS, MHM; Benjamin D.听Smith,听惭顿; Vicente聽Valero,听惭顿; Anthony聽Lucci,听惭顿; Susie X.听Sun,听惭顿, MS; Simona F.听Shaitelman,听惭顿, EdM; Melissa P.听Mitchell,听惭顿, PhD; Judy C.听Boughey,听惭顿; Richard L.听White,听惭顿; Gaiane M.听Rauch,听惭顿, PhD; Henry M.听Kuerer,听惭顿, PhD; Exceptional Responders Study Group
open access
榴莲视频 Netw Open. 2023; 6(9):e2333933. 10.1001/jamanetworkopen.2023.33933
This nonrandomized clinical trial evaluates patient-reported outcomes in a clinical trial evaluating omission of breast surgery for invasive cancers with exceptional response to neoadjuvant systemic therapy.
-
JAMA Surgery
Original Investigation
September 7, 2022
Marie聽Osdoit,听惭顿; Christina聽Yau,聽PhD; W. Fraser聽Symmans,听惭顿; Judy C.听Boughey,听惭顿; Cheryl A.听Ewing,听惭顿; Ron聽Balassanian,听惭顿; Yunn-Yi聽Chen,听惭顿; Gregor聽Krings,听惭顿; Anne M聽Wallace,听惭顿; Somaye聽Zare,听惭顿; Oluwole聽Fadare,听惭顿; Rachael聽Lancaster,听惭顿; Shi聽Wei,听惭顿, PhD; Constantine V.听Godellas,听惭顿; Ping聽Tang,听惭顿, PhD; Todd M聽Tuttle,听惭顿; Molly聽Klein,听惭顿; Sunati聽Sahoo,听惭顿; Tina J.听Hieken,听惭顿; Jodi M.听Carter,听惭顿, PhD; Beiyun聽Chen,听惭顿, PhD; Gretchen聽Ahrendt,听惭顿; Julia聽Tchou,听惭顿, PhD; Michael聽Feldman,听惭顿; Eleni聽Tousimis,听惭顿; Jay聽Zeck,听惭顿; Nora聽Jaskowiak,听惭顿; Husain聽Sattar,听惭顿; Arpana M.听Naik,听惭顿; Marie Catherine聽Lee,听惭顿; Marilin聽Rosa,听惭顿; Laila聽Khazai,听惭顿; Mara H.听Rendi,听惭顿; Julie E.听Lang,听惭顿; Janice聽Lu,听惭顿; Ossama聽Tawfik,听惭顿, PhD; Smita M.听Asare,聽BS; Laura J.听Esserman,听惭顿; Rita A.听Mukhtar,听惭顿
free access
JAMA Surg. 2022; 157(11):1034-1041. 10.1001/jamasurg.2022.4118
This study examines the association of residual ductal carcinoma in situ in surgical specimens after neoadjuvant chemotherapy with breast cancer survival end points.
-
JAMA Oncology
Original Investigation
September 16, 2021
W. Fraser聽Symmans,听惭顿; Christina聽Yau,聽PhD; Yunn-Yi聽Chen,听惭顿; Ron聽Balassanian,听惭顿; Molly E.听Klein,听惭顿; Lajos聽Pusztai,听惭顿; Rita聽Nanda,听惭顿; Barbara A.听Parker,听惭顿; Brian聽Datnow,听惭顿; Gregor聽Krings,听惭顿; Shi聽Wei,听惭顿; Michael D.听Feldman,听惭顿; Xiuzhen聽Duan,听惭顿; Beiyun聽Chen,听惭顿; Husain聽Sattar,听惭顿; Laila聽Khazai,听惭顿; Jay C.听Zeck,听惭顿; Sharon聽Sams,听惭顿; Paulette聽Mhawech-Fauceglia,听惭顿; Mara聽Rendi,听惭顿; Sunati聽Sahoo,听惭顿; Idris Tolgay聽Ocal,听惭顿; Fang聽Fan,听惭顿; Lauren Grasso聽LeBeau,听惭顿; Tuyethoa聽Vinh,听惭顿; Megan L.听Troxell,听惭顿; A. Jo聽Chien,听惭顿; Anne M.听Wallace,听惭顿; Andres聽Forero-Torres,听惭顿; Erin聽Ellis,听惭顿; Kathy S.听Albain,听惭顿; Rashmi K.听Murthy,听惭顿; Judy C.听Boughey,听惭顿; Minetta C.听Liu,听惭顿; Barbara B.听Haley,听惭顿; Anthony D.听Elias,听惭顿; Amy S.听Clark,听惭顿; Kathleen聽Kemmer,听惭顿; Claudine聽Isaacs,听惭顿; Julie E.听Lang,听惭顿; Hyo S.听Han,听惭顿; Kirsten聽Edmiston,听惭顿; Rebecca K.听Viscusi,听惭顿; Donald W.听Northfelt,听惭顿; Qamar J.听Khan,听惭顿; Brian聽Leyland-Jones,听惭顿; Sara J.听Venters,聽PhD; Sonal聽Shad,聽BS; Jeffrey B.听Matthews,聽PhD; Smita M.听Asare,聽BS; Meredith聽Buxton,聽PhD; Adam L.听Asare,聽PhD; Hope S.听Rugo,听惭顿; Richard B.听Schwab,听惭顿; Teresa聽Helsten,听惭顿; Nola M.听Hylton,听惭顿; Laura聽van 鈥檛 Veer,聽PhD; Jane聽Perlmutter,聽PhD; Angela M.听DeMichele,听惭顿; Douglas聽Yee,听惭顿; Donald A.听Berry,聽PhD; Laura J.听Esserman,听惭顿
free access
has multimedia
JAMA Oncol. 2021; 7(11):1654-1663. 10.1001/jamaoncol.2021.3690
This randomized clinical trial examines the distribution and prognosis of residual cancer burden across high-risk phenotypic subtypes of breast cancer and by different treatment groups.
-
JAMA Oncology
Original Investigation
February 13, 2020
Rita聽Nanda,听惭顿; Minetta C.听Liu,听惭顿; Christina聽Yau,聽PhD; Rebecca聽Shatsky,听惭顿; Lajos聽Pusztai,听惭顿, DPhil; Anne聽Wallace,听惭顿; A. Jo聽Chien,听惭顿; Andres聽Forero-Torres,听惭顿; Erin聽Ellis,听惭顿; Heather聽Han,听惭顿; Amy聽Clark,听惭顿; Kathy聽Albain,听惭顿; Judy C.听Boughey,听惭顿; Nora T.听Jaskowiak,听惭顿; Anthony聽Elias,听惭顿; Claudine聽Isaacs,听惭顿; Kathleen聽Kemmer,听惭顿; Teresa聽Helsten,听惭顿; Melanie聽Majure,听惭顿; Erica聽Stringer-Reasor,听惭顿; Catherine聽Parker,听惭顿; Marie C.听Lee,听惭顿; Tufia聽Haddad,听惭顿; Ronald N.听Cohen,听惭顿; Smita聽Asare; Amy聽Wilson; Gillian L.听Hirst,聽PhD; Ruby聽Singhrao; Katherine聽Steeg; Adam聽Asare,聽PhD; Jeffrey B.听Matthews,聽PhD; Scott聽Berry,聽PhD; Ashish聽Sanil,聽PhD; Richard聽Schwab,听惭顿; W. Fraser聽Symmans,听惭顿; Laura聽van 鈥榯 Veer,聽PhD; Douglas聽Yee,听惭顿; Angela聽DeMichele,听惭顿; Nola M.听Hylton,聽PhD; Michelle聽Melisko,听惭顿; Jane聽Perlmutter,聽PhD; Hope S.听Rugo,听惭顿; Donald A.听Berry,聽PhD; Laura J.听Esserman,听惭顿
free access
JAMA Oncol. 2020; 6(5):676-684. 10.1001/jamaoncol.2019.6650
This analysis of data from an ongoing open-label adaptively randomized phase 2 platform trial examines the efficacy of adding pembrolizumab to standard neoadjuvant chemotherapy in patients with early-stage, high-risk, ERBB2-negative breast cancer.
-
JAMA Surgery
Original Investigation
July 17, 2019
Jane M.听Armer,聽PhD, RN, CLT; Karla V.听Ballman,聽PhD; Linda聽McCall,聽MS; Pamela L.听Ostby,聽RN, PhD; Eris聽Zagar,聽MSN, RN; Henry M.听Kuerer,听惭顿; Kelly K.听Hunt,听惭顿; Judy C.听Boughey,听惭顿
free access
JAMA Surg. 2019; 154(9):800-809. 10.1001/jamasurg.2019.1742
This cohort study examines factors associated with lymphedema after neoadjuvant chemotherapy and axillary lymph node dissection in women with node-positive breast cancer.
-
JAMA Oncology
Original Investigation
January 1, 2019
Aman U.听Buzdar,听惭顿; Vera J.听Suman,聽PhD; Funda聽Meric-Bernstam,听惭顿; Ann Marilyn聽Leitch,听惭顿; Matthew J.听Ellis,听惭顿, PhD; Judy C.听Boughey,听惭顿; Gary W.听Unzeitig,听惭顿; Melanie E.听Royce,听惭顿; Kelly K.听Hunt,听惭顿
free access
JAMA Oncol. 2019; 5(1):45-50. 10.1001/jamaoncol.2018.3691
This phase 3 randomized clinical trial compares disease-free and overall survival among patients with operable HER2-positive breast cancer who received concurrent vs sequential administration of neoadjuvant chemotherapy.
-
JAMA Surgery
Original Investigation
December 1, 2018
Alison U.听Barron,听惭顿; Tanya L.听Hoskin,聽MS; Courtney N.听Day,聽BS; E. Shelley聽Hwang,听惭顿, MPH; Henry M.听Kuerer,听惭顿, PhD; Judy C.听Boughey,听惭顿
free access
JAMA Surg. 2018; 153(12):1120-1126. 10.1001/jamasurg.2018.2696
This study of the National Cancer Database evaluated the association of nodal positivity rates with a pathologic complete response to neoadjuvant chemotherapy among patients with cT1/cT2 cN0 triple-negative breast cancer or ERBB2-positive disease.
-
JAMA
Original Investigation
October 9, 2013
Judy C.听Boughey,听惭顿; Vera J.听Suman,聽PhD; Elizabeth A. Mittendorf, MD, PhD; Gretchen M.听Ahrendt,听惭顿; Lee G.听Wilke,听惭顿; Bret聽Taback,听惭顿; A. Marilyn聽Leitch,听惭顿; Henry M. Kuerer, MD, PhD; Monet聽Bowling,听惭顿; Teresa S.听Flippo-Morton,听惭顿; David R.听Byrd,听惭顿; David W.听Ollila,听惭顿; Thomas B.听Julian,听惭顿; Sarah A.听McLaughlin,听惭顿; Linda聽McCall,聽MS; W. Fraser聽Symmans,听惭顿; Huong T.听Le-Petross,听惭顿; Bruce G.听Haffty,听惭顿; Thomas A.听Buchholz,听惭顿; Heidi聽Nelson,听惭顿; Kelly K.听Hunt,听惭顿; for the Alliance for Clinical Trials in Oncology
free access
JAMA. 2013; 310(14):1455-1461. 10.1001/jama.2013.278932
Boughey and coauthors determine the false-negative rate for sentinel lymph node (SLN) surgery following chemotherapy in 663 women initially presenting with biopsy-proven node-positive breast cancer. In an Editorial, Morrow and Dang discuss false-negative rates and their role in determining whether to use more aggressive therapies.
![]()